Program
upacicalcet sodium hydrate
Also written as “PLS240” and “Open-Label Extension PLS240”.
Its studies are mostly in Hyperparathyroidism, Secondary · Renal Insufficiency, Chronic, led by Pathalys Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pathalys Pharma | 31 open or running | phase 3since Apr 17, 2023 | Apr 17, 2023 | Feb 22, 2032phase 3 · NCT07890584 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2023First studies: 2 phase 3 studies in Hyperparathyroidism, SecondaryFirst studyNCT05832931, NCT05836220
- Oct 16, 2026Phase 3 study in Renal Insufficiency, ChronicNCT07890584 · 56 planned · United States
Ahead
- Feb 22, 2032Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07890584
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07890584Renal Insufficiency, Chronic · United States | 3 | Not yet recruiting | Feb 22, 2032 | 56 |
| NCT05836220Hyperparathyroidism, Secondary · United States, Bulgaria, Poland and more | 3 | Completed | Aug 5, 2025 | 412 |
| NCT05832931Hyperparathyroidism, Secondary · United States, Bulgaria, Poland and more | 3 | Completed | Jul 28, 2025 | 362 |
How it is read
Names in the registry
- “PLS240”, 3 entries
- “Open-Label Extension PLS240”, 2 entries
Codes read as this program: PLS240.
Conditions, from the studies’ own filings
- Hyperparathyroidism, Secondary, 2 studies
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.